Impact of low sodium values on survival outcomes of patients with cancer receiving immune checkpoint inhibitors.

Autor: Karaoğlan BB; Ankara University Faculty of Medicine, Department of Medical Oncology, Ankara, TÜRKİYE.; Ankara University, Cancer Research Institute, Ankara 06620, TÜRKİYE., Yekedüz E; Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, MA 02215, USA., Yazgan SC; Ankara University Faculty of Medicine, Department of Medical Oncology, Ankara, TÜRKİYE.; Ankara University, Cancer Research Institute, Ankara 06620, TÜRKİYE., Mocan EE; Ankara University Faculty of Medicine, Department of Medical Oncology, Ankara, TÜRKİYE.; Ankara University, Cancer Research Institute, Ankara 06620, TÜRKİYE., Köksoy EB; Ankara University Faculty of Medicine, Department of Medical Oncology, Ankara, TÜRKİYE.; Ankara University, Cancer Research Institute, Ankara 06620, TÜRKİYE., Yaşar HA; Ankara University Faculty of Medicine, Department of Medical Oncology, Ankara, TÜRKİYE.; Ankara University, Cancer Research Institute, Ankara 06620, TÜRKİYE., Şenler FÇ; Ankara University Faculty of Medicine, Department of Medical Oncology, Ankara, TÜRKİYE.; Ankara University, Cancer Research Institute, Ankara 06620, TÜRKİYE., Utkan G; Ankara University Faculty of Medicine, Department of Medical Oncology, Ankara, TÜRKİYE.; Ankara University, Cancer Research Institute, Ankara 06620, TÜRKİYE., Demirkazık A; Ankara University Faculty of Medicine, Department of Medical Oncology, Ankara, TÜRKİYE.; Ankara University, Cancer Research Institute, Ankara 06620, TÜRKİYE., Akbulut H; Ankara University Faculty of Medicine, Department of Medical Oncology, Ankara, TÜRKİYE.; Ankara University, Cancer Research Institute, Ankara 06620, TÜRKİYE., Ürün Y; Ankara University Faculty of Medicine, Department of Medical Oncology, Ankara, TÜRKİYE.; Ankara University, Cancer Research Institute, Ankara 06620, TÜRKİYE.
Jazyk: angličtina
Zdroj: Immunotherapy [Immunotherapy] 2024; Vol. 16 (12), pp. 821-828. Date of Electronic Publication: 2024 Jul 17.
DOI: 10.1080/1750743X.2024.2370231
Abstrakt: Background: Low serum sodium affects cancer prognosis, but its impact on immunotherapy is unclear. Objective: Assessing the association of pre- and post-ICI treatment sodium levels with survival. Methods: We retrospectively analyzed patients receiving ICI in January 2012-December 2023, collecting serum sodium levels at treatment initiation and 4 weeks post-ICI, with overall survival (OS) as the primary outcome. Results: Low sodium was observed in 125 and 119 patients pre-and post-treatment respectively. Pre-ICI and post-ICI low sodium correlated with decreased OS [10.6 vs. 22.9 months ( p = 0.001) and 11.6 vs. 27.2 months ( p = 0.009)]. Multivariate analysis identified pre-ICI low sodium [HR: 1.685; 95% CI: 1.050-2.705; p = 0.031] as an independent risk factor for worse OS. Conclusion: Low baseline serum sodium was an independent risk factor for poor OS in patients treated with ICIs.
Databáze: MEDLINE
Externí odkaz: